Press Release
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2…
FALLS CHURCH, Va., May 01, 2026 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE:NOC) continues to…
New York City, NY, May 01, 2026 (GLOBE NEWSWIRE) — You are well aware that…
Dublin, May 01, 2026 (GLOBE NEWSWIRE) — The “Bevacizumab Biosimilars Market Report 2026” has been…
DUBAI, United Arab Emirates, May 01, 2026 (GLOBE NEWSWIRE) — B2BROKER Group, a global fintech…
Dublin, May 01, 2026 (GLOBE NEWSWIRE) — The “Adalimumab, Infliximab and Etanercept Biosimilars Market Report…
ALEXANDRIA, Va., May 01, 2026 (GLOBE NEWSWIRE) — Whitespace today announced the general availability of…